The Gynecologic Cancer Research Foundation

Our Mission:


The mission of Gynecologic Cancer Research Foundation is the prevention and early treatment of gynecologic pre-cancers and cancers. It our core belief of that many gynecologic cancer deaths can be prevented by early detection or prevention of precancerous condition.


Why We Chose This Mission

We recognize that:

·      Research into the causes and treatments of non-HPV related gynecologic pre-cancers and cancers is severely lacking.

·      Limited resources in many low and income countries (as well as for marginalized women in middle or high income countries) severely limit access to gynecologic cancer screening services.

·      Inadequate training of healthcare providers limits early detection of gynecologic pre-cancers and cancers.


Our Goals


The current goals of the Gynecologic Cancer Research Foundation is to fund research to:

·      Understand the underlying biological mechanisms that cause the development of non–HPV related vulvar pre-cancers and cancers.

·      Develop effective and safe long-term treatments for vulvar precancerous diseases such as lichen sclerosus (a vulvar cancer precursor).

·      Develop and implement cost-effective screening cervical dysplasia and cancer strategies based on new technologies to enable screening of millions of women in resource poor countries.



Types of Human Papilloma Virus

Of which at least 13 are cancer causing, known as the high risk type. Human Papilloma Virus (HPV) types 16 and 18 cause 70% of cervical cancers and precancerous cervical lesions. HPV can also cause cancers of the anus, vulva, vagina, penis, throat and tongue.


Of New Cases worldwide

Are found to be related to cervical cancer. It is the second most common cancer in women living in less developed regions, and can be caused through sexually acquired infection with high risk HPV. In 2012, approximately 270 000 women died from cervical cancer; more than 85% of these deaths occurring in low- and middle-income countries.


Women Will be affected by lichen sclerosus

4-7% of women with lichen sclerosus will develop vulvar cancer unless optimally treated. Only optimal treatment of lichen sclerosus with ultra-high potency corticosteroids has been shown to lower the risk of developing vulvar cancer.

Our Strategies:

The current strategies of the Gynecologic Cancer Research Foundation that we are using to meet our goals:

  •  Fund research in the use of platelet rich plasma for the treatment of vulvar lichen sclerosus.

  • Fund research in the use of fractional CO 2 lasers for the treatment of vulvar lichen sclerosus.

  • Fund research to determine the optimal cervical pre-cancer and cancer screening method in HIV positive and HIV negative Cambodian women.

  • Fund research to determine the specific inflammatory pathways involved in vulvar lichen sclerosus by examining gene expression and genetic polymorphisms in families affected by lichen sclerosus.

  • Develop partnerships with governmental agencies (Ministries of Health in developing countries), NGOs and other private foundations, and industry leaders to implement our research and to develop gynecologic cancer screening programs.


There is no simple and reliable way to test for ovarian cancer in women who do not have any signs or symptoms. More than 160,000 women die annually from ovarian cancer.


Meet our Board of Directors

Get to know the Board of Directors, who are passionate about their research and hopes for this foundation. Click below to see who is involved. 

Learn About Our CUrrent Research

Click below to read more about what we are currently researching. 

Make a Donation

Proceeds go directly to supporting research towards treating gynecologic cancers and pre-cancers. Click below to see how you can help.